Janux reports FY2021 net loss $32.7M; cash $375M; IND filings for two TRACTr programs on track for 2022

Janux Therapeutics, Inc.

Cash, cash equivalents and short-term investments $375.0M at Dec 31, 2021, vs $7.8M a year ago.
Net loss $13.4M for Q4 2021 and $32.7M for FY2021; R&D expense $26.2M (FY2021).
PSMA-TRACTr IND submission expected H1 2022; EGFR-TRACTr IND expected H2 2022.
Nominated first TRACIr candidate, a PD-L1xCD28 costimulatory bispecific; IND planned for 2023.
Appointed Byron Robinson, Ph.D., J.D., as Chief Strategy Officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.